Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy.
Department of Biology, University of Pisa, Pisa, Italy.
Front Immunol. 2023 Jun 8;14:1197053. doi: 10.3389/fimmu.2023.1197053. eCollection 2023.
DNAM-1 is a major NK cell activating receptor and, together with NKG2D and NCRs, by binding specific ligands, strongly contributes to mediating the killing of tumor or virus-infected cells. DNAM-1 specifically recognizes PVR and Nectin-2 ligands that are expressed on some virus-infected cells and on a broad spectrum of tumor cells of both hematological and solid malignancies. So far, while NK cells engineered for different antigen chimeric receptors (CARs) or chimeric NKG2D receptor have been extensively tested in preclinical and clinical studies, the use of DNAM-1 chimeric receptor-engineered NK cells has been proposed only in our recent proof-of-concept study and deserves further development. The aim of this perspective study is to describe the rationale for using this novel tool as a new anti-cancer immunotherapy.
DNAM-1 是一种主要的 NK 细胞激活受体，与 NKG2D 和 NCR 一起，通过结合特定的配体，强烈促进介导杀伤肿瘤或病毒感染的细胞。DNAM-1 特异性识别 PVR 和 Nectin-2 配体，这些配体表达在一些病毒感染的细胞和广泛的血液恶性肿瘤和实体恶性肿瘤细胞上。到目前为止，虽然针对不同抗原嵌合受体 (CAR) 或嵌合 NKG2D 受体的 NK 细胞已在临床前和临床研究中进行了广泛测试，但仅在我们最近的概念验证研究中提出了使用嵌合 DNAM-1 受体工程化 NK 细胞，值得进一步发展。本观点研究的目的是描述使用这种新型工具作为新型抗癌免疫疗法的基本原理。
